Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Dermatologic 3Breast 3Tumor-Agnostic 2Thoracic 2Sarcoma 2Lymphoid 2Gynecologic 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7Lymphoma, Non-Hodgkin 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Hodgkin Disease 5Hematologic Neoplasms 5Lymphoma, Follicular 4Leukemia, Myeloid, Acute 4Burkitt Lymphoma 4Neuroblastoma 3Myelodysplastic Syndromes 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Waldenstrom Macroglobulinemia 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Mycosis Fungoides 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Hairy Cell 2Intraocular Lymphoma 2Immunoblastic Lymphadenopathy 2

Interventions

pembrolizumab 5Gemcitabine 5Albumin-Bound Paclitaxel 5Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Bevacizumab 4venetoclax 3spartalizumab 3abemaciclib 3Sirolimus 3Pemetrexed 3Paclitaxel 3Leucovorin 3Ipilimumab 3Fluorouracil 3Doxorubicin 3Cisplatin 3Bortezomib 3130-nm albumin-bound paclitaxel 3manganese chloride 2fludarabine phosphate 2fludarabine 2copanlisib 2Taxes 2Midazolam 2Irinotecan 2Interleukin-2 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × CTLA-4 Antigen × Lymphoid × Clear all
NCT03502733 2026-05-13

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
64 enrolled
Lymphoid

Lymphoma, Neoplasm Metastasis

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡